Neurogene
NGNE
45 hedge funds and large institutions have $8.66M invested in Neurogene in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 13 closing their positions.
0.2% less ownership
Funds ownership: 2.2% → 2% (-0.2%)
13% less funds holding
Funds holding: 52 → 45 (-7)
28% less capital invested
Capital invested by funds: $12M → $8.66M (-$3.32M)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
60% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.18M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$748K |
| 3 |
Jane Street
New York
|
+$31.3K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$25K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$995K |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$819K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$368K |
| 4 |
BlackRock
New York
|
-$142K |
| 5 |
Renaissance Technologies
New York
|
-$128K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CGL
51
Clarius Group LLC
Seattle,
Washington
| – | -$15K | -1,176 | Closed |
|
52
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$13K | -1,015 | Closed |
|
53
Goldman Sachs
New York
| – | -$10K | -787 | Closed |
|
|
LP
54
LMR Partners
London,
United Kingdom
| – | -$8K | -628 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$165 | -16 | -62% |
|
NGNE Hedge Fund Activity: Q4 2022 in Review
45 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2022, worth a combined $8.66M — down 28% from $12M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NGNE and 7 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 6 added.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $1.18M. The largest seller was Point72 Asset Management, cutting an estimated $995K.
- 45 institutional investors held Neurogene (NGNE) as of Q4 2022, down from 52 in Q3 2022.
- Funds reported $8.66M of Neurogene stock for Q4 2022, down 28% quarter-over-quarter.
- 7 funds opened new Neurogene positions in Q4 2022 and 13 closed out, a net change of -6 holders.
- The largest Neurogene buyer in Q4 2022 was Lynx1 Capital Management, an estimated $1.18M added.
- The largest Neurogene seller in Q4 2022 was Point72 Asset Management, an estimated $995K sold.
Based on aggregated 13F filings for Q4 2022.